Stubbs Alderton & Markiles’ client, OS National, a premier nationwide title insurance agency, announced this week that it has been acquired by Opendoor, which makes instant online offers to buy homes. The purchase allows Opendoor to integrate title, escrow and closings into its online buying and selling experience.
To read the full press release visit here.
Stubbs Alderton & Markiles attorneys representing OS National in this matter were Greg Akselrud, Louis Wharton, Michael Shaff, Madeleine Barenholtz and Brent Armitage.
About OS National
OS National is building the premier nationwide title insurance agency. Founded on a deeply rooted passion to better serve their customers and their evolving needs, they are approaching title insurance differently – with the customer first. Keeping this at the forefront, they are able to define what OS National is, what they stand for, and how they will interact with you. And, it is simple. They are not your typical title company. OS National is redefining title services. Visit https://osnational.com.
For more information about our Internet, Digital Media and Entertainment Practice contact Greg Akselrud at
Stubbs Alderton & Markiles’ client Edesa Biotech Inc., a clinical-stage biopharmaceutical company, has announced the completion of its business combination transaction with Stellar Biotechnologies, Inc. pursuant to a share exchange agreement entered into on March 7, 2019. The combined company will be called Edesa Biotech, Inc. and commenced trading on the Nasdaq Capital Market on June 10, 2019 under the symbol "EDSA."
To read the full press release visit here.
Stubbs Alderton & Markiles’ attorneys representing Edesa Biotech in this transaction are Jonathan Friedman and Brent Armitage.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company focused on efficiently developing innovative treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. Edesa also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications. The company is based in Toronto, Canada, with U.S. offices in Southern California.
For more information about our Corporate & Business Matters practice area please contact Jonathan Fredman at
Stubbs Alderton & Markiles' client VivoAquatics, the leading provider of innovative water management and real-time monitoring platform for hotels, resorts, fitness clubs, and other commercial facilities announced it has secured Series A financing led by Level Equity, a growth equity firm focused on software and automation companies. The funding represents another milestone for the company as leading brands and properties continue to adopt the VivoPoint software and IoT platform to proactively manage the risks and costs of water within a facility while improving the guest experience.
To read the full press release visit here.
Stubbs Alderton & Markiles’ attorneys representing VivoAquatics in this deal are John McIlvery, Kelly Laffey, and Brent Armitage.
For more information about our Venture Capital and Emerging Growth practice, contact John McIlvery at